Practical issues with amisulpride in the management of patients with schizophrenia

Clinical Drug Investigation

Volumn 28, Issue 8, 2008, Pages 465-477

  Pani, Luca ^a,b   Villagrán, José M ^c   Kontaxakis, Vassilis P ^d   Alptekin, Köksal ^e  

^a INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

^b SARDEGNA RICERCHE   (Italy)

^c Jerez Hospital   (Spain)

^d NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^e DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Amisulpride, therapeutic use; Antipsychotics, therapeutic use; Clozapine, therapeutic use; Haloperidol, therapeutic use; Olanzapine, therapeutic use; Risperidone, therapeutic use; Schizophrenia; Switch therapy

Indexed keywords

AMISULPRIDE; ANTIPARKINSON AGENT; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; CYAMEMAZINE; HALOPERIDOL; INOTROPIC AGENT; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; THIORIDAZINE;

ADD ON THERAPY; AGRANULOCYTOSIS; AKATHISIA; AMENORRHEA; ANTICHOLINERGIC EFFECT; BODY MASS; BRIEF PSYCHIATRIC RATING SCALE; CARDIOVASCULAR DISEASE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG UTILIZATION; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; EFFECT SIZE; ENDOCRINE DISEASE; EPILEPSY; EXTRAPYRAMIDAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; HYPOTENSION; LOADING DRUG DOSE; MONOTHERAPY; NEUTROPENIA; OBSERVATIONAL STUDY; OSTEOPOROSIS; PARKINSONISM; PATIENT CARE; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; QUALITY OF LIFE; RATING SCALE; REBOUND; RECOMMENDED DRUG DOSE; REVIEW; SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOM; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN; WITHDRAWAL SYNDROME;

ANTIPSYCHOTIC AGENTS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SULPIRIDE;

EID: 46749130922     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200828080-00001     Document Type: Review

References (72)

1. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003 Jun; 60 (6): 553-64
2. Leucht S, Pitschel-Walz G, Engel RR, et al. Amisulpride, an unusual 'atypical' antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002 Feb; 159 (2): 180-90
3. Ziegenbein M, Calliess IT. Clozapine and ziprasidone: a useful combination in patients with treatment-resistant schizophrenia. J Neuropsychiatry Clin Neurosci 2006 Spring; 18 (2): 246-7
4. Lerner V, Bergman J, Borokhov A, et al. Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy. Clin Neuropharmacol 2005 Mar-Apr; 28 (2): 66-71
5. Meltzer HY. Treatment of suicidality in schizophrenia. Ann N Y Acad Sci 2001 Apr; 932: 44-58; discussion 58-60
6. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999; 25 (2): 233-55
7. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62 Suppl. 7: 22-31
8. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 Suppl. 1: 1-93
9. Rettenbacher MA, Ebenbichler C, Hofer A, et al. Early changes of plasma lipids during treatment with atypical antipsychotics. Int Clin Psychopharmacol 2006 Nov; 21 (6): 369-72
10. Koro CE, Fedder DO, L'Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002 Nov; 59 (11): 1021-6
11. Scheen AJ, De Hert MA. Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab 2007 Jun; 33 (3): 169-75
12. Peuskens J, De Hert M, Mortimer A. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. Int Clin Psychopharmacol 2007 May; 22 (3): 145-52
13. Burns T, Chabannes JP, Demyttenaere K. Switching antipsychotic medications: general recommendations and switching to amisulpride. Curr Med Res Opin 2002; 18 (4): 201-8
14. Mortimer A, Martin S, Loo H, et al. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol 2004 Mar; 19 (2): 63-9
15. Sechter D, Peuskens J, Fleurot O, et al. Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology 2002 Dec; 27 (6): 1071-81
16. Chivers JK, Gommeren W, Leysen JE, et al. Comparison of the in-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors. J Pharm Pharmacol 1988 Jun; 40 (6): 415-21
17. Perrault G, Depoortere R, Morel E, et al. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 1997 Jan; 280 (1): 73-82
18. Puech A, Fleurot O, Rein W. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta Psychiatr Scand 1998 Jul; 98 (1): 65-72
19. Martinot JL, Paillere-Martinot ML, Poirier MF, et al. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology (Berl) 1996 Mar; 124 (1-2): 154-8
20. Peuskens J, Bech P, Moller HJ, et al. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride Study Group. Psychiatry Res 1999 Nov 8; 88 (2): 107-17
21. Moller HJ, Boyer P, Fleurot O, et al. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. Psychopharmacology (Berl) 1997 Aug; 132 (4): 396-401
22. Mielke DH, Gallant DM, Kessler C. An evaluation of a unique new antipsychotic agent, sulpiride: effects on serum prolactin and growth hormone levels. Am J Psychiatry 1977 Dec; 134 (12): 1371-5
23. Alfredsson G, Wiesel FA. Relationships between clinical effects and monoamine metabolites and amino acids in sulpiride-treated schizophrenic patients. Psychopharmacology (Berl) 1990; 101 (3): 324-31
24. Curran MP, Perry CM. Amisulpride: a review of its use in the management of schizophrenia. Drugs 2001; 61 (14): 2123-50
25. Boyer P, Lecrubier Y, Puech AJ, et al. Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 1995 Jan; 166 (1): 68-72
26. Danion JM, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry 1999 Apr; 156 (4): 610-6
27. Loo H, Poirier-Littre MF, Theron M, et al. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 1997 Jan; 170: 18-22
28. Paillere-Martinot ML, Lecrubier Y, Martinot JL, et al. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 1995 Jan; 152 (1): 130-4
29. Soni SD, Mallik A, Schiff AA. Sulpiride in negative schizophrenia: a placebo-controlled double-blind assessment. Hum Psychopharmacol 1990; 5: 233-8
30. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004; 64 (20): 2291-314
31. McKeage K, Plosker GL. Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs 2004; 18 (13): 933-56
32. Coulouvrat C, Dondey-Nouvel L. Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol 1999 Jul; 14 (4): 209-18
33. Baptista T, Alastre T, Contreras Q, et al. Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy men: relationship with body weight regulation. Pharmacopsychiatry 1997 Nov; 30 (6): 250-5
34. Baptista T, Molina MG, Martinez JL, et al. Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy premenopausal women: relationship with body weight regulation. Pharmacopsychiatry 1997 Nov; 30 (6): 256-62
35. Buvat-Herbaut BJ. Neuroendocrine effects of sulpiride [in French]. Lille Med 1979 Nov 17; Suppl. 1: 37
36. Ros LT. Changes in the endocrine system in the course of sulpiride therapy [in Polish]. Pol Merkur Lekarski 2001 Dec; 11 (66): 532-4
37. Peuskens J. Switching to amisulpride. Curr Med Res Opin 2002; 18 Suppl. 3: s23-8
38. Weiden PJ. Switching in the era of atypical antipsychotics: an updated review. Postgrad Med 2006 Sep; Special Report: 27-44
39. Buckley PF. Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents. J Clin Psychiatry 2007; 68 Suppl. 6: 5-9
40. Davis JM. The choice of drugs for schizophrenia. N Engl J Med 2006 Feb 2; 354 (5): 518-20
41. De Nayer A, De Hert M, Scheen A, et al. Belgian consensus on metabolic problems associated with atypical antipsychotics. Int J Psychiatry Clin Pract 2005; 9 (2): 130-7
42. Linden M, Scheel T, Eich FX. Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride. J Psychopharmacol 2006 Nov; 20 (6): 815-23
43. Linden M, Eich FX, Pyrkosch L. Do differences in atypical antipsychotics matter in routine practice? Medication switch from olanzapine and risperidone to amisulpride. Int Clin Psychopharmacol 2007 May; 22 (3): 175-8
44. Shore D, Matthews S, Cott J, et al. Clinical implications of clozapine discontinuation: report of an NIMH workshop. Schizophr Bull 1995; 21 (2): 333-8
45. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 Sep 22; 353 (12): 1209-23
46. Weiden PJ. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. J Clin Psychiatry 2007; 68 Suppl. 1: 12-9
47. Borison RL. Changing antipsychotic medication: guidelines on the transition to treatment with risperidone. The Consensus Study Group on Risperidone Dosing. Clin Ther 1996 Jul-Aug; 18 (4): 592-607; discussion 591
48. Naranjo CA, Sproule BA, Knoke DM. Metabolic interactions of central nervous system medications and selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1999 May; 14 Suppl. 2: S35-47
49. Taylor D. Pharmacokinetic interactions involving clozapine. Br J Psychiatry 1997 Aug; 171: 109-12
50. Committee on Safety of Medicines. UK Medicines Control Agency. Drug-induced neutropenia and agranulocytosis. Curr Prob 1993; 10: 10-1
51. Chong SA, Tan CH, Lee HS. Atrial ectopics with clozapine-risperidone combination. J Clin Psychopharmacol 1997 Apr; 17 (2): 130-1
52. Carriere P, Bonhomme D, Lemperiere T. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur Psychiatry. 2000 Aug; 15 (5): 321-9
53. Chabannes JP, Pelissolo A, Farah S, et al. Evaluation of efficacy and tolerance of amisulpride in treatment of schizophrenic psychoses [in French]. Encephale 1998 Jul-Aug; 24 (4): 386-92
54. Speller JC, Barnes TR, Curson DA, et al. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms: amisulpride v. haloperidol. Br J Psychiatry 1997 Dec; 171: 564-8
55. Wetzel H, Grunder G, Hillert A, et al. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology: a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group. Psychopharmacology (Berl) 1998 Jun; 137 (3): 223-32
56. Lambert M, Naber D, Eich FX, et al. Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatr Scand 2007 Feb; 115 (2): 106-13
57. Lerner V, Libov I, Kotler M, et al. Combination of 'atypical' antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. Prog Neuropsychopharmacol Biol Psychiatry 2004 Jan; 28 (1): 89-98
58. Zink M, Dressing H. Augmenting atypical antipsychotic medications with clozapin [in German]. Nervenarzt 2005 Sep; 76 (9): 1092, 4-8, 100-2
59. Agelink MW, Kavuk I, Ak I. Clozapine with amisulpride for refractory schizophrenia. Am J Psychiatry 2004 May; 161 (5): 924-5
60. Buckley P, Miller A, Olsen J, et al. When symptoms persist: clozapine augmentation strategies. Schizophr Bull 2001; 27 (4): 615-28
61. Zink M, Henn FA, Thome J. Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses. Eur Psychiatry 2004 Feb; 19 (1): 56-8
62. Kämpf P, Agelink MW, Naber D. Augmentation of clozapine with amisulpride: a promising therapeutic approach to refractory schizophrenic symptoms. Pharmacopsychiatry 2005 Jan; 38 (1): 39-40
63. Kämpf P, Agelink MW, Mass R, et al. Amisulpride in addition to clozapine: a retrospective study indicates improved efficacy and good tolerability. German J Psychiatry 2003; 6: 64-8
64. Munro J, Matthiasson P, Osborne S, et al. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand 2004 Oct; 110 (4): 292-8
65. Ziegenbein M, Wittmann G, Kropp S. Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: a clinical observation. Clin Drug Invest 2006; 26 (3): 117-24
66. Schoemaker H, Claustre Y, Fage D, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997 Jan; 280 (1): 83-97
67. Assion HJ, Reinbold H, Lemanski S, et al. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine: a randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry 2008 Jan; 41 (1): 24-8
68. Genç Y, Taner E, Candansayar S. Comparison of clozapine- amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv Ther 2007 Jan-Feb; 24 (1): 1-13
69. Ziegenbein M, Sieberer M, Kuenzel HE, et al. Augmentation of clozapine with amisulpride in patients with treatment-resistant schizophrenia: an open clinical study. Germ J Psychiatr 2006; 9: 17-21
70. Zink M, Knopf U, Henn FA, et al. Combination of clozapine and amisulpride in treatment-resistant schizophrenia: case reports and review of the literature. Pharmacopsychiatry 2004 Jan; 37 (1): 26-31
71. Cook B, Hoogenboom G. Combined use of amisulpride and clozapine for patients with treatment-resistant schizophrenia. Australas Psychiatry 2004 Mar; 12 (1): 74-6
72. Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. Int Clin Psychopharmacol 2006 Mar; 21 (2): 99-103